Observational studyBMC emergency medicine2026
External prognostic validation of the EHMRG score for risk stratification and disposition decisions in acute heart failure.
Observational study in BMC emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05710302 (Investigation of the Diagnostic Accuracy of EHMRG Risk Score in Patients With Acute Heart Failure), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Investigation of the Diagnostic Accuracy of EHMRG Risk Score in Patients With Acute Heart Failure
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRisk stratification in patients with Acute Heart Failure (AHF) is critical for optimizing disposition decisions in the Emergency Department (ED). While clinical judgment is the cornerstone of management, “borderline” patients often present a challenge. The Emergency Heart Failure Mortality Risk Grade (EHMRG) score was developed to objectively predict short-term mortality. This study aims to prospectively validate the EHMRG score for predicting 30-day all-cause mortality and to evaluate its performance for 7-day mortality as a secondary outcome, as well as its concordance with clinician disposition decisions.
methodsThis prospective, single-center, observational external prognostic validation study enrolled adult patients presenting to the ED with AHF between August 2022 and January 2023. The EHMRG score was calculated for all patients but blinded to treating physicians to prevent influence on decision-making. The primary outcome was 30-day all-cause mortality. Seven-day all-cause mortality was evaluated as a secondary outcome due to the limited number of early events. Discriminatory performance for short-term mortality was assessed using Receiver Operating Characteristic (ROC) curve analysis.
resultsA total of 237 patients were included (median age 76 years; 53.6% female). The overall mortality rate was 16.9% at 30 days and 5.9% at 7 days. The EHMRG score demonstrated moderate discriminative ability with an Area Under the Curve (AUC) of 0.755 (95% CI: 0.67–0.84) for 30-day mortality and 0.741 (95% CI: 0.61–0.87) for 7-day mortality. Notably, no deaths occurred in the very low- or low-risk groups (Negative Predictive Value > 97%). However, discordance was observed between clinical judgment and risk scores; 27% of patients were discharged despite being classified as moderate to very high risk by EHMRG. Notably, 12.5% of the 30-day non-survivors originated from this discharged group.
conclusionsThe EHMRG score demonstrated acceptable discrimination for predicting 30-day mortality in this cohort of emergency department patients with acute heart failure. When used alongside clinical judgment, the score may assist clinicians in identifying patients who could potentially be considered for safe discharge.
trial registrationClinicalTrials.gov, NCT05710302. Registered January 24, 2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.